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Quantitative Analysis of 
Inflammation in Orbital 
Fat of Thyroid-associated 
Ophthalmopathy Using MRI Signal 
Intensity
Tomoaki Higashiyama, Maki Iwasa & Masahito Ohji
We quantitatively analyzed inflammation in orbital fat from cases of thyroid-associated 
ophthalmopathy (TAO) using short-tau inversion recovery (STIR) sequences from magnetic resonance 
imaging. The signal intensity ratios (SIRs) of orbital fat as well as the superior rectus (SR), inferior rectus 
(IR), lateral rectus (LR), medial rectus (MR), and superior oblique (SO) muscles on STIR images were 
measured in 70 eyes from 70 treatment-naive TAO patients (active TAO group, 19 patients; inactive 
TAO group, 51 patients) and 20 eyes from 20 controls. The mean SIR in the active TAO group was 
significantly higher than that in the inactive TAO group and controls (P < 0.001). The SIR of orbital fat in 
all TAO patients was significantly (P < 0.001) positively correlated with that of the extraocular muscles: 
SR (r = 0.64), IR (r = 0.55), LR (r = 0.58), MR (r = 0.71), and SO (r = 0.65). The SIR of orbital fat had a 
significant positive correlation with the CAS (r = 0.53, P < 0.001). The measurements of SIRs in orbital 
fat may be useful in evaluating the activity in tissues of TAO patients.
Thyroid-associated ophthalmopathy (TAO) is the most prevalent extra-thyroidal manifestation of thyroid dis-
ease1. TAO is an immune-mediated inflammatory disease in which the levels of anti-thyroid antibodies are ele-
vated. The disease causes increased orbital fat and enlarged extraocular muscles in the orbit1,2. Some clinical signs 
and symptoms of TAO arise from enlarged orbital tissues2–7. TAO has previously been classified as either the 
predominantly increased orbital fat type or predominantly enlarged extraocular muscle type5,8. Younger patients 
tend to have increased orbital fat, whereas older patients are more likely to have enlarged extraocular muscles2.
We previously reported the quantitative evaluation of inflammation in the extraocular muscles of active 
TAO patients using short-tau inversion recovery (STIR) sequences of magnetic resonance imaging (MRI)9. 
Inflammation can be quantitatively evaluated in STIR images because the high signal intensity indicates edema 
caused by inflammation in extraocular muscles10–16. Our previous report demonstrated that the pretreatment 
signal intensity in the extraocular muscles of TAO patients was significantly higher than that in controls by MRI9. 
The signal intensity after methylprednisolone pulse therapy was significantly lower than the pretreatment inten-
sity. In addition, the signal intensity in patients with TAO was significantly correlated with the clinical activity 
score (CAS). Another study also obtained similar findings15.
However, inflammation in the orbital fat of TAO patients has not been studied quantitatively, which has left 
some question unanswered, such as the comparison of the signal intensities in orbital fat among active TAO 
patients, inactive TAO patients, and controls as well as the correlation of the inflammation in orbital fat with the 
inflammation in the extraocular muscles, CAS, and patient’s age.
Thus, we investigated the signal intensity of orbital fat in TAO patients and controls using the MRI STIR 
sequences.
Results
Comparison of the orbital fat signal intensity ratios (SIRs) among the active TAO group, inac-
tive TAO group, and controls. The active (CAS ≥ 3/7) TAO group included 19 patients, and the inactive 
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TAO group included 51 patients. The mean CASs were 3.74 ± 0.73 (range, 3–5) in the inactive TAO group and 
1.00 ± 0.85 (range, 0–2) in the inactive TAO group.
The mean orbital fat SIRs were 1.94 ± 0.19 in the active TAO group, 1.70 ± 0.21 in the inactive TAO group, 
and 1.65 ± 0.16 in the controls. The mean SIR in the active TAO group was significantly higher than that in the 
inactive TAO group and controls (P < 0.001) (Fig. 1, Table 1). The mean SIR in the inactive TAO patients was 
not significantly higher than that in the controls (P = 0.62). Table 1 also shows the comparison of the extraocular 
muscle SIRs among the groups.
Correlations between the orbital fat SIRs and the extraocular muscle SIRs. The mean SIRs in all 
TAO patients were 1.99 ± 0.73, 2.23 ± 0.69, 1.86 ± 0.39, 2.10 ± 0.51 and 1.73 ± 0.43 in the superior rectus (SR), 
inferior rectus (IR), lateral rectus (LR), medial rectus (MR), and superior oblique (SO) muscles, respectively. The 
orbital fat SIRs showed significant (P < 0.001) positive correlations with those of the extraocular muscles: SR 
(r = 0.64), IR (r = 0.55), LR (r = 0.58), MR (r = 0.71) and SO (r = 0.65) (Fig. 2, Table 2).
Correlation between orbital fat SIRs and the CAS. The correlation between the orbital fat SIR and the 
CAS was analyzed. The mean value in all TAO patients was 1.74 ± 1.47. The orbital fat SIR showed a significant 
positive correlation with the CAS (r = 0.53, P < 0.001) (Fig. 3).
Correlations between orbital fat SIRs and age. A significant correlation was not observed between the 
orbital fat SIR and age (r = 0.19, P = 0.11) (Fig. 4A). Very weak significant positive correlations were observed 
between the SIRs of some of the extraocular muscles and age: IR (r = 0.41, P < 0.001), LR (r = 0.24, P = 0.047), 
MR (r = 0.36, P = 0.002) (Fig. 4B).
The mean ages were 41.5 ± 8.6 years (range 14–50 years) in the young group (36 patients) and 62.6 ± 6.2 years 
(range 51–78 years) in the old group (34 patients). Very weak significant positive correlations were observed 
between the SIRs of some of the extraocular muscles and age in the young group: SR (r = 0.46, P = 0.005), IR 
(r = 0.38, P = 0.23), LR (r = 0.34, P = 0.04) and MR (r = 0.34, P = 0.04). However, a significant correlation was not 
observed between the extraocular muscles SIRs and age in the old group (Table 3). Significant correlations were 
not observed between the orbital fat SIR and age in either group.
Figure 1. Comparison of the orbital fat signal intensity ratio (SIR) among the active thyroid-associated 
ophthalmopathy (TAO) group, inactive TAO group, and controls. The plots and bars of the active TAO group 
(circle), inactive TAO group (triangle) and controls (diamond) indicate the mean and standard deviation. The 
mean SIR in the active TAO group was significantly higher than that in the inactive TAO group and controls 
(P < 0.001). The mean SIR in the inactive TAO group was not significantly higher than that in the controls 
(P = 0.62).
Active TAO Inactive TAO Controls
P value
Active TAO vs. 
Inactive TAO
Active TAO 
vs. Controls
Inactive TAO 
vs. Controls
FAT 1.94 ± 0.19 1.70 ± 0.21 1.65 ± 0.16 <0.001 <0.001 0.62
SR 2.56 ± 0.70 1.78 ± 0.62 1.08 ± 0.25 <0.001 <0.001 <0.001
IR 2.76 ± 0.72 2.03 ± 0.58 1.32 ± 0.28 <0.001 <0.001 <0.001
LR 2.14 ± 0.45 1.75 ± 0.32 1.34 ± 0.18 <0.001 <0.001 <0.001
MR 2.61 ± 0.53 1.91 ± 0.36 1.47 ± 0.24 <0.001 <0.001 <0.001
SO 2.14 ± 0.47 1.58 ± 0.30 1.26 ± 0.22 <0.001 <0.001 <0.001
Table 1. Comparison among the signal intensity ratios of orbital fat in the active thyroid-associated 
ophthalmopathy (TAO) group, inactive TAO group, and controls. TAO = thyroid-associated ophthalmopathy; 
FAT = orbital fat, SR = superior rectus; IR = inferior rectus; LR = lateral rectus; MR = medial rectus; 
SO = superior oblique.
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Discussion
The mean SIR in the active TAO group was significantly higher than that in the inactive TAO group and controls 
in this study. Chen et al. reported a comparison of macrophage infiltration into orbital fat between TAO patients 
and controls17. These authors showed that macrophage infiltration into orbital fat was greater in TAO patients 
than in controls. Histological examination to quantitatively evaluate inflammation in the orbital fat in a clinical 
setting, however, is almost impossible for many TAO patients. Hence, the noninvasive use of MRI STIR sequences 
to quantitatively evaluate the signal intensity of orbital fat inflammation may be useful in TAO patients. The cur-
rent study revealed that orbital fat inflammation may develop due to increased disease activity in TAO patients.
A significant positive correlation was observed between the SIR of orbital fat and that of the extraocular mus-
cles in this study. Other studies previously reported that TAO patients could be classified as having predominantly 
increased orbital fat or predominantly enlarged extraocular muscles5,8. Hiromatsu et al. investigated the cytokine 
profiles of orbital fat and extraocular muscle tissues in TAO patients8. These authors reported that the cytokine 
profiles were different between these two tissue sources. Kuriyan et al. investigated the effect of cyclooxygenase 
inhibitors on adipogenesis and proliferation of orbital fibroblasts in the two TAO subtypes (the predominantly fat 
Figure 2. Correlation between the signal intensity ratio (SIR) of the orbital fat and those of extraocular muscles. 
The orbital fat SIR showed significant (P < 0.001) positive correlations with those of extraocular muscles: SR 
(r = 0.64), IR (r = 0.55), LR (r = 0.58), MR (r = 0.71), and SO (r = 0.65). FAT = orbital fat; SR = superior rectus; 
IR = inferior rectus; LR = lateral rectus; MR = medial rectus; SO = superior oblique.
r P value
SR 0.64 <0.001
IR 0.55 <0.001
LR 0.58 <0.001
MR 0.71 <0.001
SO 0.65 <0.001
Table 2. Correlations between orbital fat and extraocular muscle signal intensity ratios (SIRs). FAT = orbital fat, 
SR = superior rectus; IR = inferior rectus; LR = lateral rectus; MR = medial rectus; SO = superior oblique.
Figure 3. Correlation between the orbital fat signal intensity ratio (SIR) and clinical activity scores. The orbital 
fat SIR showed a significant positive correlation with the Clinical Activity Score (CAS) (r = 0.53, P < 0.001). SIR 
of FAT = signal intensity ratio of orbital fat.
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compartment enlargement type and predominantly extraocular muscle enlargement type)5. Orbital fibroblasts 
were isolated and established from TAO patients undergoing orbital decompression. The authors reported that 
the effect of cyclooxygenase inhibitors was different for the two subtypes because the cyclooxygenase inhibitors 
significantly decreased proliferation and adipogenesis in the orbital fibroblasts of patients with the predominantly 
extraocular muscle enlargement type but not the predominantly fat compartment enlargement type. In contrast, 
our study showed that the orbital fat and extraocular muscle SIRs were significantly correlated. We showed that 
the orbital fat inflammation might develop in conjunction with that in extraocular muscles, although the patho-
logical pathways in these tissues might be different.
The orbital fat SIR showed a significant positive correlation with the CAS in this study. We previously reported 
a significant positive correlation between the extraocular muscle SIRs and CAS in TAO patients9. Another study 
also reported that a significant positive correlation was found between the extracocular muscle SIRs and the 
Mourits score, which is the basis for the CAS in TAO patients14. Our current study revealed that the orbital fat SIR 
was also correlated with the CAS.
A significant correlation was not found between the orbital fat SIR and age, whereas a very weak significant 
positive correlation was observed between some of the extraocular muscle SIRs and age. In other review arti-
cles, younger patients were more likely to exhibit increased orbital fat without extraocular muscle enlargement, 
whereas older patients were more prone to exhibit severe extraocular muscle enlargement2,18,19. Murakami et al. 
investigated the relationship between age and extraocular muscle enlargement by CT in TAO patients20. The 
frequency of extraocular muscle enlargement was correlated with age in older patients, which agreed with our 
results. To the best of our knowledge, the relationship between age and orbital fat inflammation has not been pre-
viously reported. The current study showed that the SIR of orbital fat did was not significantly correlated with age. 
Inflammation in the fat might not be strongly affected by age, unlike that in the extraocular muscles.
The present study has several limitations. First, the sample size was small, with only 70 patients enrolled. 
Second, the mean CAS was low. It is known that the clinical signs of TAO differ among races, and the CAS tends 
to be low in Japanese patients with TAO21, which could be the reason for the low CAS observed in this study.
In conclusion, measuring the orbital fat SIR may be useful for evaluating disease activity in TAO patients.
Methods
Subjects. The institutional review board of Shiga University of Medical Science approved this retrospective 
study. The study adhered to the tenets of the Declaration of Helsinki. Each patient provided written informed 
consent.
In total, 70 eyes from 70 patients with TAO (52 female, 18 male; mean ± SD age 51.8 ± 13.0 years, range 14–78 
years) and 20 eyes from 20 volunteer controls (4 female, 16 male; mean age 36.8 ± 11.3 years, range 20–54 years) 
Figure 4. Correlation of age with the signal intensity ratio (SIR) of orbital fat and extraocular muscles. 
The orbital fat SIR did not show a significant correlation with age (r = 0.19, P = 0.11) (A). The SIRs of some 
extraocular muscles showed significant positive correlations with age: IR (r = 0.42, P < 0.001), LR (r = 0.24, 
P = 0.047) and MR (r = 0.36, P = 0.002) (B). FAT = orbital fat; IR = inferior rectus; LR = lateral rectus; 
MR = medial rectus.
Young group Old group
r P value r P value
FAT 0.28 0.10 −0.15 0.39
SR 0.46 0.05 −0.14 0.42
IR 0.38 0.02 0.09 0.60
LR 0.34 0.04 −0.17 0.33
MR 0.34 0.04 −0.16 0.37
SO 0.32 0.06 0.11 0.55
Table 3. Correlations between orbital fat and extraocular muscle signal intensity ratios (SIRs) and age. 
FAT = orbital fat, SR = superior rectus; IR = inferior rectus; LR = lateral rectus; MR = medial rectus; 
SO = superior oblique.
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were included in this study at the Department of Ophthalmology, Shiga University of Medical Science Hospital, 
from April 2008 to December 2016. The eye in which the mean orbital fat SIR was higher was selected as rep-
resentative of the patient, and the right eye was selected as representative of the control. Only treatment-naive 
TAO patients who had a high level of serum thyroid autoantibodies were included. The normal serum thyroid 
autoantibody ranges are as follows: thyrotropin receptor antibody determined by the first and second generation 
assays (first normal: 0–15%, second normal: 0–0.9 IU/L), thyroid stimulating antibody (normal 0–120%), thyroid 
peroxidase antibody (normal 0–15.9 IU/mL), and thyroglobulin antibody (normal 0–27.9 IU/mL). If patients had 
an orbital disease or an inflammatory disease in the orbit, they were excluded.
Signal intensity measurements. All patients were subjected to orbital MRI with a standard head coil. The 
MRI was performed on a 3.0-tesla MRI unit (Achieva 3.0 T Quasar Dual; Royal Philips Electronics, Amsterdam, 
The Netherlands).
The signal intensities of the orbital fat and the SR, IR, LR, MR, and SO muscles were measured in the STIR 
and T2-weighted images (Fig. 5). The regions of interest (ROIs) were drawn around the tissues on coronal 
T2-weighted images. The drawn ROIs were superimposed on the STIR images at the same level, and the signal 
intensities were measured.
To standardize the signal intensity in each tissue, the signal intensity of brain white matter (WM) on STIR 
images was measured as the “standard” tissue, which was similar to the protocol described in our previous stud-
ies9,16. The SIRs between the orbital fat or extraocular muscles and the WM of the same slice was calculated. The 
highest value among the mean SIRs of three consecutive slices in each tissue was considered representative of the 
SIR for that tissue.
Assessment of CAS. The CAS (maximum score 7 points) was measured in all TAO patients. The CAS con-
sists of seven findings: spontaneous retrobulbar pain; pain on attempted up or down gaze; redness of the conjunc-
tiva; redness of the eyelids; inflammation of the caruncle and/or plica; swelling of the eyelids; and conjunctival 
edema22,23. Patients with CAS ≥ 3/7 were considered as having active TAO22. TAO patients were divided into two 
groups (the active CAS group and inactive CAS group) in the comparison analysis.
Statistical analysis. All statistical analyses were performed using SPSS Statistics 22 software (IBM, Armonk, 
NY, USA). The normality of the numerical variables was evaluated using the Shapiro–Wilk test. The Tukey HSD 
test was used to compare the SIRs among the active TAO group, inactive TAO group, and controls. Pearson’s 
product–moment correlation coefficient or Spearman’s rank correlation coefficient were used to analyze the cor-
relations between the orbital fat SIRs and those of extraocular muscles and the correlations between the SIRs and 
CAS and age in all TAO patients. The values are expressed as the mean ± SD. A P value of less than 0.05 indicated 
statistical significance.
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